Background: Recent evidence suggests that chronic low back pain is associated with plastic changes in the brain that can be modified by neuromodulation strategies. This study investigated the efficacy of transcranial direct current stimulation (tDCS) combined simultaneously with peripheral electrical stimulation (PES) for pain relief, disability and global perception in patients with chronic low back pain (CLBP). Methods: Ninety-two patients with CLBP were randomized to receive 12 sessions on nonconsecutive days of anodal tDCS (primary motor cortex, M1), 100 Hz sensory PES (lumbar spine), tDCS + PES or sham tDCS + PES. Pain intensity (11-point numerical rating scale), disability and global perception were applied before treatment and four weeks, three months and six months post randomization. Results: A two points reduction was achieved only by the tDCS + PES (mean reduction [MR] = À2.6, CI95% = À4.4 to À0.9) and PES alone (MR = À2.2, CI95% = À3.9 to À0.4) compared with the sham group, but not of tDCS alone (MR = À1.7, CI95% = À3.4 to À0.0). In addition to maintaining the analgesic effect for up to three months, tDCS + PES had a higher proportion of respondents in different cutoff points. Global perception was improved at four weeks and maintained three months after treatment only with tDCS + PES. None of the treatments improved disability and the affective aspect of pain consistently with pain reduction.
Introduction
Low back pain is one of the world's leading causes of disability (Global Burden of Disease Study 2013 Collaborators 2015 and is often associated with psychiatric comorbidities and substantial socioeconomic impacts (Gore et al., 2012) . Recent estimates indicate a prevalence of 11.9%, mostly affecting women and people aged between 40 and 80 years (Hoy et al., 2012) .
Recent evidence shows that chronic low back pain is associated with a decrease in grey matter in the dorsolateral prefrontal cortices (DLPFC) bilaterally and in the right thalamus (Apkarian et al., 2004) , and reorganization of primary somatosensory cortex (Flor et al., 1997) . In addition, chronic increasing unpleasantness and intensity of pain is correlated with decrease in grey matter in the brainstem and in the somatosensory cortex of chronic back patients (Schmidt-Wilcke et al., 2006) . Thus, therapeutic strategies targeting brain structures in areas involved in the processing of pain (Melzack, 1999) may be the best method for effective blockade or reduction of pain signals. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions (Fenton et al., 2009; Antal et al., 2010; Mori et al., 2010; Bolognini et al., 2015; Fagerlund et al., 2015; Mohomad et al., 2015) . However, as a monotherapy for pain relief, this therapy still has controversial results (Luedtke et al., 2012 (Luedtke et al., , 2015 O'Connell et al., 2013 O'Connell et al., , 2014 Vaseghi et al., 2014) .
One way to optimize the effects of tDCS and increase the likelihood of pain modulation is the combination of tDCS with other techniques to achieve synergistic and additive effects. Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors (Sluka and Walsh, 2003) capable of promoting segmental (Melzack and Wall, 1965) and extrasegmental (Kalra et al., 2001) analgesia. Both tDCS Paulus, 2000, 2001) and PES (Mima et al., 2004; Murakami et al., 2007; Chipchase et al., 2011) are able to modulate the neuronal activity at the primary motor cortex (M1), promoting transient or non-transient neuroplastic effects. The modulation of this region is related to a decrease in pain, because it influences important areas related to pain processing, such as the thalamus, the cingulate cortex and the periaqueductal grey matter (Garcia-Larrea et al., 1999; Maarrawi et al., 2007; Peyron et al., 2007; Pagano et al., 2012) .
In the recent literature, better results have been found when the techniques were performed in combination rather than alone Schabrun et al., 2014) . However, no randomizedcontrolled trials were conducted to investigate the combination of these techniques in controlling chronic low back pain.
The aim of this study was to investigate the efficacy of tDCS combined simultaneously with PES for relieving pain, improve disability and global perception in patients with chronic low back pain.
Methods

Study design
This study was a randomized, double-blind, placebocontrolled clinical trial with a 2 9 2 factorial design, in which two treatments (factors) with two levels (real and sham stimulations) resulted in four distinct interventions. The present investigation was approved by the local ethics committee and registered at Clinicaltrials.gov as NCT01896453.
Subjects
The study involved 92 patients from the Clinical School of Physiotherapy of the Physiotherapy School (Faculty of Medicine, University of São Paulo) and from a rehabilitation centre (Irmandade Santa Casa de Miseric ordia of São Paulo), both located in São Paulo, Brazil. The inclusion criteria were as follows: (1) age between 18 and 60 years, (2) medical diagnosis of nonspecific low back pain presenting with pain for at least 3 months, (3) spontaneous search for treatment of low back pain and (4) signature of the informed consent. The patients who reported the following conditions during medical consultation were excluded: (1) low back pain assessed by NRS <4, (2) spinal surgery lasting <6 months, (3) transcutaneous electric nerve stimulation (TENS) treatment lasting <6 months, (4) previous treatment with tDCS, (5) disk herniation with nerve root compression and neurological impairment, (6) neurological, psychiatric and rheumatological diseases that could lead to misleading results, (7) use of pacemakers or other implanted devices, (8) pregnancy, (9) use of psychoactive drugs and (10) excessive use of alcoholic beverages and medications.
Treatment protocol
The participants were randomly divided into four treatment groups as follows: (1) real transcranial direct current stimulation (tDCS-r) + real peripheral electrical stimulation (PES-r), (2) real transcranial direct current stimulation (tDCS-r) + sham peripheral electrical stimulation (PES-s), (3) sham transcranial direct current stimulation (tDCS-s) + real peripheral electrical stimulation (PES-r) and (4) sham transcranial direct current stimulation (tDCSs) + sham peripheral electrical stimulation (PES-s).
Treatments were given for 4 weeks with three sessions per week (nonconsecutive), totalling 12 electrical stimulation sessions. The primary variable (pain intensity) was assessed before, during (pre and post session) and after each intervention. The secondary variables and confounding factors (depression and anxiety) were assessed at the baseline and at the end of the total intervention period. Patient's follow-up was conducted in weeks 4, 12 and 24 after randomization. All evaluations were performed by a single researcher who, like the patients themselves, was unaware of the stimulation group to which the patients belonged. The full version of this study protocol has been published previously (Hazime et al., 2015) .
Transcranial direct current stimulation
The tDCS was applied by a DC generator powered by a nine-volt battery (Activadose II, Activa tek Inc., Salt Lake City, UT, USA), using two electrodes (35 cm 2 [5 9 7 cm]; Ibramed, Amparo, SP, Brazil) covered with a sponge moistened with saline (1%) and fixed to the head with elastic bands.
The anodal electrode was positioned on C3 or C4 (contralateral to the side of the pain complaint), and the cathodal electrode was placed on the supraorbital region ipsilateral to the region of pain complaint . The groups that received real tDCS (tDCS-r) were treated with an electrical current intensity of 2 mA, an electrical current density of 0.057 mA/cm 2 , and an application time of 20 min (O'Connell et al., 2014) . Sham tDCS (tDCS-s) groups received brain stimulation with the same parameters, but the exposure time with real stimulation was only 30 s (O'Connell et al., 2013) .
Peripheral electrical stimulation
The peripheral stimulation was applied by means of an electrical current device generating a balanced rectangular, biphasic and asymmetric wave (Neurodyn III; Ibramed). The current was applied using four adhesive electrodes (5 9 9 cm; Valutrode, Axelgaard Manufacturing Co., Ltd. -CA, USA). The electrodes were in parallel and bilaterally placed on the lumbar segment reported as the most painful, with a gap of 30 mm between them. The groups that received real PES (PES-r) were treated with strong though comfortable (sensory threshold) current intensity (Bennett et al., 2011 ), a pulse frequency of 100 Hz, a pulse duration of 200 ls, and an application time of 40 min (Cheing et al., 2003) . Groups with simulated PES (PES-s) were treated with the same stimulation parameters, but the application time, as with simulated tDCS, was only 30 s.
Outcome measures
After the participants met and subsequently adhered to the eligibility criteria and after they signed the informed consent, details like personal data, clinical history, radiographic findings (if any), and anthropometric characteristics were collected through a structured interview. Later, a clinical, psychological and functional evaluation was performed according to IMMPACT group recommendations (Dworkin et al., 2005) . All scales and questionnaires have been assessed their measurement properties, translated and cross-culturally adapted to the Brazilian population.
Pain intensity was assessed through a numerical scale of 11 points (0-10), were 0 accounting for no pain and 10 for the worst pain possible. The secondary outcomes included: sensory and affective aspects of pain assessed on the short version of the McGill questionnaire (SF-MPQ; Menezes Costa Lda et al., 2011) ; physical functioning assessed on the Roland Morris disability questionnaire; the highest number of responses is related to greater disability because of low back pain (Nusbaum et al., 2001; Costa et al., 2007 Costa et al., , 2008 ; perception of global effect assessed by the scale of global perceived effect that assesses the perceived level of the patient's recovery from the treatment, comparing the initial symptoms with those of the last days (Costa et al., 2008) .
Confounding factors
Depression and anxiety were assessed at the beginning and the end of treatment by the Brazilian version of the Beck Depression Inventory (BDI; Gorenstein and Andrade, 1996) and Visual Analog Scale (VAS), respectively (Williams et al., 2010) .
Symptoms and adverse events
The record of symptoms and adverse events resulting from the use of tDCS and TENS is passively collected by the patient's spontaneous reports. Active collection uses a questionnaire with records of the duration and intensity of adverse symptoms reported by the patient.
Sample size determination
The sample size was estimated based on the data from previous studies and to have a substantial sample size we choose only 10% reduction in pain intensity, measured by the numerical rating scale (NRS) for pain. Effect size, the probability of type 1 (a), and the probability of type 2 (b) errors were 0.33, 0.05 and 0.20, respectively. According to the sample size calculation (Faul et al., 2007) , a total of 75 participants would be necessary. However, to account for a potential 20% sample loss, a sample size of 92 participants (23 per group) was chosen.
Randomization and allocation concealment
The patients were allocated to one of the four treatment groups by means of random-number-generating software. The randomization and allocation concealment were carried out by an external collaborator, not a research participant, who organized patients and their previously allocated treatments in individual opaque envelopes.
Statistical analysis
Inferential analyses were conducted based on the analysis with intention to treat. Linear mixed models were used to identify the differences between the groups with real stimulation (tDCS, PES and tDCS + PES) and the simulated group (sham). The baseline values for the primary and secondary outcomes and for confounding variables (anxiety and depression scores) were entered into the model as covariates. When necessary, post hoc comparisons were performed using the Bonferroni correction for multiple comparisons. Effect sizes was defined as Cohen, 1988) . Analysis of the cumulative proportion of respondents with different cutoff points was performed according to Farrar et al. (2006) . All data were analysed using the IBM SPSS Statistics for Windows, Version 20 (IBM Corp. Armonk, NY, USA). The significance level adopted was 5%.
Results
Of 158 eligible patients, 66 were excluded because they did not fulfill the study criteria (n = 62) and refused to participate in the experiment (n = 4).
There were no protocol deviations from the study as planned.
Six patients did not complete the 12-session treatment for the following reasons: fracture in upper limb (five sessions attended -tDCS group), breast reduction surgery (eight sessions -tDCS group), surgery to remove abdominal tumour (eight sessions -Sham group), loss of interest in treatment (three sessions -tDCS + PES group), job change (six sessions -tDCS + PES group), and hysterectomy (11 sessions -Sham group). Fig. 1 shows the numbers of participants analysed at each time point. The participants agreed to undergo reevaluations even if they did not complete the 12-session protocol, except for one patient allocated to the tDCS group and another allocated to the tDCS + PES group.
Demographic characteristics are shown in Table 1 . Initial and posttreatment clinical outcomes as well as the results after follow-up (3 and 6 months) are shown in Table 2 .
Primary outcome
Immediate analgesic effect
Comparisons between the sham group and the tDCS, PES and tDCS + PES groups showed clinically significant analgesic effects (reduction of two points in NRS) only for the PES and tDCS + PES groups (Supporting Information Table S1 ). Fig. 2 compare the cumulative proportions of patients' responses to treatments performed with different cutoff points immediately after each of 12 sessions.
3.1.2 Analgesic effect in the short, medium and long term Table 3 shows the results of analgesic effects in the short time period (4 weeks). Medium (3 months), and long term (6 months) are described in Supporting Information Tables S2 and S3 . Compared with the sham group, only PES and tDCS + PES groups achieved a minimum clinically reduction of two points on 11-point NRS. Mean pain reduction and effect size (95% CI) were À2.2 and 1.03 (0.4 to 1.6) and À2.6 and 1.23 (0.6 to 1.9) for PES and tDCS + PES, respectively. The maintenance of the analgesic effect for 3 months was achieved only by the tDCS + PES group. No effects were observed after the 6 months of follow-up. Cumulative proportions of respondents are described as Supporting Information (Figs. S1-S3 ).
Secondary outcomes
Sensory and affective aspects of pain
No significant or clinically important changes were found after 4 weeks in any of the active groups compared with the sham group (Table 3 ). In the third month of follow-up, only the tDCS group showed significant and clinically important reductions in the affective pain rating index (MR = À2.1, CI 95% = À3.8 to À0.3, and MR = À1.9; Supporting Information Table S2 ). Six months after treatment none of the active groups achieved clinically important changes (Supporting Information  Table S3 ).
Disability
No clinically important changes in disability were achieved after 4 weeks (Table 3) , 3 months, and 6 months of treatment (Supporting Information  Tables S2 and S3) .
Global perceived effect
Clinically important changes were found only in the tDCS + PES group (Table 3) . After 3 months of treatment, only the tDCS + PES and tDCS groups showed clinically important differences in relation to the sham group (Supporting Information Table S2 ). At the end of 6 months, tDCS + PES group showed significant improvement in global perception (M = 1.91, CI95% = 0.1 to 3.8), but only tDCS alone reached two points difference on GPE scale (M = 2.2, CI95% = 0.3 to 4.0; Supporting Information Table S3 ).
Adverse effects
Adverse symptoms and effects considered unpleasant by the patients are shown in Table 4 .
Patients' satisfaction with assistance
The patients were very satisfied with the assistance and said they would return to the clinic for future services or treatments (Supporting Information  Table S4 ).
Discussion
Pain reduction
After 4 weeks of treatment, the minimum clinically important difference, compared with the sham group, was achieved only by the tDCS + PES and PES groups. Only the tDCS + PES treatment was able to maintain pain intensity reduction at clinically important levels for up to 3 months, although after six-month follow-up there were no differences between the active and sham groups. The results of both treatments were similar in terms of pain intensity; nevertheless, the number of respondents was clinically higher in the tDCS + PES combination. No clinical effect in reducing pain was found for tDCS alone compared with the sham treatment.
To the best of our knowledge, this is the first randomized double-blind clinical trial to investigate the efficacy of tDCS combined with PES for relieving pain in patients with chronic low back pain. Previous trials with a single session achieved 37% reduction of pain with tDCS + PES compared with the preintervention condition for the treatment of neurogenic pain in the arm ) and 25% reduction for recurrent lumbar pain (Schabrun et al., 2014) . Both studies reached statistically significant levels for pain relief; however, clinically significant reductions with tDCS alone were observed only in the study conducted by Schabrun et al. (2014) . It is noteworthy that our results showed a superior analgesic effect of tDCS + PES and PES alone compared to sham condition and not with baseline values of each group, which could lead to a misinterpretation as clinical pain relief comparing with pre-treatment does not mean that is different from the placebo. In this sense, our results denotes a more robust and reliable clinical findings. The action mechanisms of tDCS associated with PES are not entirely clear. It is possible that the effects of the two techniques can be combined, thus potentiating the analgesic effect (Schabrun et al., 2014) . This effect may be the result of the metaplasticity phenomenon. Anodal tDCS over M1 increases transcranial magnetic stimulation motor evoked potential (MEP) by means of an excitatory effect (Nitsche and Paulus, 2000) . On the other hand, recent studies have suggested that high-frequency PES at the sensory level reduces MEP and cortical excitability (Mima et al., 2004; Murakami et al., 2007) . The combination of an inhibitory technique (high-frequency PES at the sensory level) with another excitatory intervention (anodal tDCS) may potentiate the effect of isolated techniques via homeostatic plasticity (Bienenstock et al., 1982; Nitsche et al., 2007) . The modulation of the synaptic plasticity threshold with tDCS + PES seems to be able to optimize the neurophysiological effect of these two techniques towards increased neuronal excitability at M1 and greater analgesic efficacy (Muller-Dahlhaus and Ziemann, 2015) .
Our results show clinically important benefits of tDCS + PES for pain relief sustained for up to 3 months postintervention. The pain reduction at clinically significant levels with tDCS + PES, tDCS and PES found by Schabrun et al. (2014) was not sustained for 3 days postintervention.
The differences between our findings and those of previous studies may be due partly to the experimental design used. We opted for a more feasible management in clinical practise, in which patients attended rehabilitation services two or three times per week on alternate days instead of on five consecutive days. Because the stimulation parameters remained similar to the previous studies (Cheing et al., 2003; O'Connell et al., 2014) , the most reasonable explanation for this effect seems to be a longer period of application (weeks). Our study involved one of the longest treatment periods with neuromodulation via electrical currents for pain management (Nitsche et al., 2008; Nitsche and Paulus, 2011; O'Connell et al., 2014) , though keeping a viable scheme in clinical practise. The demonstration of a significant analgesic effect may open a new window for the clinical use of these techniques.
It is also possible that the combination of the techniques led to a potentiating of the opioid effect of each technique isolated. High-frequency PES produces a segmental inhibition via gate control (Melzack and Wall, 1965) and descending inhibition via d-opioid mechanisms (Sluka et al., 2000; Kalra et al., 2001) . In tDCS, the polarized currents are capable of inducing changes in the potential of neuronal membrane and in the excitability of cells and fibres beyond the stimulation period Paulus, 2000, 2001) . The changes in cortical excitability promoted by tDCS act via release of endogenous opioids in the mid anterior cingulate cortex and in the periaqueductal grey matter (Maarrawi et al., 2007) , acting predominantly via l-opioid mechanisms (DosSantos et al., 2012) . Stimulation of the motor cortex can also inhibit thalamic sensory neurons and enhance the activity of neurons of the periaqueductal grey matter, modulating the descending pain inhibition (Pagano et al., 2012) . Thus, it is possible that in acting together, they led to a more intense opioid activation via l and d-opioid mechanisms, but this mechanism needs to be demonstrated by future research.
In our study, although the use of anodal tDCS alone over M1 showed a reduction in two points in NRS compared with baseline, this analgesic effect did Cut-offs: <20% means minimally clinically important change; ≥30% means moderately clinically important change; ≥50% means substantial clinically important change. tDCS, transcranial direct current stimulation; PES, peripheral electrical stimulation. not occur when compared with sham condition (MR = À1.7, CI95% = À3.4 to À0.0). A mean pain reduction achieved by the tDCS alone did not reach a minimum clinical significance value established as two points or 30% in NRS (Dworkin et al., 2008) . Moreover, compared with sham treatment, the magnitude of the tDCS effect (CI95%) means that treating chronic low back pain with this technique alone can result even in no effect. Differences between our 12 nonconsecutive day's program and the traditional five consecutive sessions (Fregni et al., 2006a,b; Antal et al., 2010; Mori et al., 2010) might have influenced the tDCS results (Alonzo et al., 2012) . However, recent studies have shown that even applied consecutively, tDCS fails to induce relief for chronic pain (Luedtke et al., 2012 (Luedtke et al., , 2015 O'Connell et al., 2013; Wrigley et al., 2013) . Two recent metaanalysis studies showed conflicting results about the treatment of chronic pain with tDCS (O'Connell et al., 2014; Vaseghi et al., 2014) . The lack of homogeneity in techniques and outcomes associated with individual variability appears to be the reason for controversy. Regarding the technique itself, the high variability in neurophysiological response, in addition to low focality, can significantly impact the change in the neuronal excitability and plasticity induced by tDCS. The causes of high variability are not fully understood, but some intrinsic and extrinsic factors have been suggested as modifiers of cortical excitability (Ridding and Ziemann, 2010) .
Secondary outcomes
A clinically important change in recovery perception was consistent with a reduction in pain intensity only in the tDCS + PES group. The affective aspect of pain exhibited a clinically significant reduction only for the tDCS group in the third month posttreatment that was not consistent with a pain reduction compared with sham treatment. Although the main purpose of the interventions was pain relief, the lack of effect on disability was not expected. It is possible that perceptions, beliefs and other psychological factors may have been influenced the disability scores (Mannion et al., 2001; Grotle et al., 2004) . In addition, the fact that our treatments were exclusively passive interventions might not have influenced positively the outcomes related to functional recovery. Thus, tDCS or PES alone and even tDCS combined with PES should be implemented with exercise therapy to have an impact on functionality in low back pain patients.
Limitations
This study did not carry out an analysis of subgroups. High scores in patient satisfaction may have been influenced our results (Table 4) .
Conclusion
Peripheral electrical stimulation alone or tDCS combined with PES is effective for immediate and shortterm pain relief in patients with chronic nonspecific low back pain. In the medium term, only the combination of tDCS and PES kept pain relief at clinically relevant levels. This combination also resulted in a higher proportion of patients with a clinically significant reduction in pain, indicating that these two neuromodulation techniques may have a synergistic effect. Our results do not support the use of tDCS alone in the treatment of chronic low back pain.
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